Article

Overexpression of interferon-activated gene 202 (Ifi202) correlates with the progression of autoimmune glomerulonephritis associated with the MRL chromosome 1.

Laboratory of Anatomy, Department of Biomedical Sciences, Graduate School of Veterinary Medicine, Hokkaido University Sapporo, Japan.
Lupus (impact factor: 2.34). 02/2010; 19(8):897-905. DOI:10.1177/0961203310362534 pp.897-905
Source: PubMed

ABSTRACT B6.MRLc1(82-100) congenic mice carrying the telomeric region of lupus-prone MRL chromosome 1 develop autoimmune glomerulonephritis (GN). The GN susceptibility locus of B6.MRLc1(82-100) contains the interferon activated gene 200 (Ifi200) family, which consists of Ifi202, 203, 204, and 205. Recently, Ifi202 was suggested as a candidate gene for murine lupus. In this study, we assessed the association between Ifi200 family and GN in several disease models. We compared the expression of Ifi200 family members in 24 organs between the C57BL/6 and B6.MRLc1(82-100). The expressions of Ifi200 family members differed between strains, and the most dramatic differences appeared in Ifi202 expression. Briefly, in the blood, immune organs, lungs, and testes mRNA expression was higher in B6.MRLc1(82-100) mice. In the kidney and immune organs, only Ifi202 expression increased with the development of GN in B6.MRLc1(82-100), and significant differences from C57BL/6 were observed even before disease onset. Ifi202 expression in the kidneys of BXSB, NZB/WF1, and MRL/lpr was also significantly high in the early- and late-disease stages. Furthermore, laser microdissection-reverse-transcriptase-polymerase chain reaction analysis confirmed the high Ifi202 expression in all areas of B6.MRLc1(82-100) kidneys. In conclusion, in the Ifi200 family, Ifi202 expressions in the kidney and immune organs significantly increased with GN progression.

0 0
 · 
0 Bookmarks
 · 
29 Views
  • Source
    Article: Activation of type I interferon pathway in systemic lupus erythematosus: association with distinct clinical phenotypes.
    [show abstract] [hide abstract]
    ABSTRACT: Growing evidence over the last few years suggests a central role of type I IFN pathway in the pathogenesis of systemic autoimmune disorders. Data from clinical and genetic studies in patients with systemic lupus erythematosus (SLE) and lupus-prone mouse models, indicates that the type I interferon system may play a pivotal role in the pathogenesis of several lupus and associated clinical features, such as nephritis, neuropsychiatric and cutaneous lupus, premature atherosclerosis as well as lupus-specific autoantibodies particularly against ribonucleoproteins. In the current paper, our aim is to summarize the latest findings supporting the association of type I IFN pathway with specific clinical manifestations in the setting of SLE providing insights on the potential use of type I IFN as a therapeutic target.
    Journal of Biomedicine and Biotechnology 01/2011; 2011:273907. · 2.44 Impact Factor

Full-text

View
1 Download
Available from

Keywords

24 organs
 
BXSB
 
candidate gene
 
disease onset
 
dramatic differences
 
early-
 
expressions
 
GN progression
 
GN susceptibility locus
 
Ifi200 family
 
Ifi200 family members
 
Ifi202 expressions
 
immune organs
 
interferon activated gene 200
 
laser microdissection-reverse-transcriptase-polymerase chain reaction analysis
 
late-disease stages
 
lupus-prone MRL chromosome 1
 
murine lupus
 
telomeric region
 
testes mRNA expression
 

O Ichii